We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

WERFEN

Werfen provides diagnostic instruments for critical care and hemostasis to meet the testing needs of medical professi... read more Featured Products: More products

Download Mobile App




Werfen and VolitionRx Partner to Advance Diagnostic Testing for Antiphospholipid Syndrome

By LabMedica International staff writers
Posted on 12 Sep 2025

Antiphospholipid syndrome (APS) is a rare autoimmune disorder that causes the immune system to produce abnormal antibodies, making the blood “stickier” than normal. More...

This condition increases the risk of blood clots that can lead to stroke, heart attack, pulmonary embolism, or deep vein thrombosis. It is also associated with recurrent miscarriages and pregnancy complications. Current diagnostic methods rely on blood tests that require repeated confirmation over time, leaving a gap for improved and more efficient tools.

VolitionRx (Henderson, NV, USA), a multinational epigenetics company, has signed a research license and exclusive commercial option rights agreement for APS with Werfen’s Immunoassay Technology Center (Barcelona, Spain), a worldwide leader in specialized diagnostics. Under the agreement, Werfen will evaluate the clinical utility of Volition’s proprietary Nu.Q® NETs assay on its automated platforms. The assay focuses on detecting neutrophil extracellular traps (NETs), which play a significant role in the clotting complications seen in APS patients.

Initial technology transfer has already succeeded, with the Nu.Q® NETs assay integrated into Werfen’s ACL AcuStar® platform. Early data on NET detection in APS patients have been encouraging, showing the test’s potential as a risk indicator for thrombosis. The Nu.Q® assay represents the first CE-IVD biomarker being investigated for APS, positioning it as a potential breakthrough in disease monitoring and diagnosis.

The collaboration aims to validate the assay in larger clinical studies and determine its role in routine APS patient care. If successful, the tool could provide improved diagnostic information, enable more personalized treatments, and support long-term monitoring with a simple, low-cost blood test. This development could reduce reliance on current multi-step diagnostic protocols and enhance patient care globally.

“We believe that Volition’s Nu.Q® NETs test is the first CE-IVD biomarker being investigated in APS and could provide not only improved diagnostic information to aid clinical decision-making and personalize care, but also a low-cost test to continue to monitor these patients throughout their lifetimes,” said Remi Rabeuf, Vice President Corporate Alliances & Strategic Partnerships, VolitionRx.

“We are excited to validate further and complete a clinical utility study to determine the potential role of this marker as a risk indicator of thrombosis in APS patients, allowing a better management of this very complex syndrome,” added Marta Palicio, Werfen’s Immunoassay Technology Center Innovation R&D Director. “This could open the possibility to enlarge Werfen’s portfolio in APS testing.”

Related Links:
VolitionRx
Werfen


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Collection and Transport System
PurSafe Plus®
8-Channel Pipette
SAPPHIRE 20–300 µL
Laboratory Software
ArtelWare
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.